OKYO Pharma Market Sentiment

OKYO Pharma Ltd

OKYONASDAQ

Trade with Public

$1.44

0.053.6%

마지막 업데이트: Oct 9, 4:00 PM

개요 뉴스 실적 전망 이벤트 목표가 재무심리지분 현황 비교 주식 보고서

OKYO Pharma Market Sentiment - Benzinga

OKYO Pharma Market Sentiment

Market sentiment signals for OKYO Pharma (OKYO): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▲ 0.1% short float

Options Flow— N/A

Insider Activity— N/A

Analyst Consensus

Buy

3 analysts

Options Flow (P/C)

—

Avg Consensus PT

+293.8%

Highest Price Target

+386.1%

Piper Sandler

Lowest Price Target

+247.2%

HC Wainwright & Co.

Short Interest

0.1%

Declining — Bullish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Jul 13, 2026	HC Wainwright & Co.	Yi Chen—	+247.2%	$7 → $5	Maintained	Buy
Feb 20, 2026	Piper Sandler	Biren Amin—	+386.1%	$7	Initiate	Overweight
Dec 8, 2025	B. Riley Securities	William Woods—	+247.2%	$5	Initiate	Buy
Sep 23, 2025	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
May 5, 2025	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
Feb 18, 2025	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
Feb 14, 2025	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
Feb 10, 2025	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
Oct 24, 2024	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
Oct 16, 2024	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
Aug 27, 2024	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
Jul 12, 2024	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
Jul 11, 2024	HC Wainwright & Co.	Yi Chen—	+386.1%	$7 → $7	Maintained	Buy
Mar 22, 2024	HC Wainwright & Co.	Yi Chen—	+386.1%	$6 → $7	Maintained	Buy
Jan 8, 2024	HC Wainwright & Co.	Yi Chen—	+247.2%	$4 → $5	Maintained	Buy
Dec 5, 2023	HC Wainwright & Co.	Yi Chen—	+177.8%	$4 → $4	Maintained	Buy
Nov 2, 2023	HC Wainwright & Co.	Yi Chen—	+177.8%	$4	Initiate	Buy

More with Benzinga EdgeGet Access

Insider & Market Activity News

PRO
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share

OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced

Benzinga Newsdesk

PRO
OKYO Pharma Announces Non-Executive Director John Brancaccio Buys 5,000 Shares At $1.48/Share, Bringing Total Holdings To 35,201 Shares

Benzinga Newsdesk

PRO
OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced

Benzinga Newsdesk

PRO
OKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per Share

Benzinga Newsdesk

PRO
OKYO Pharma Says Chairman Gabriele Cerrone, Through Panetta Partners, Increases His Holdings With Purchase Of 25,000 Ordinary Shares At $1.40 Per Share

Benzinga Newsdesk

PRO
OKYO Pharma's Panetta Partners Buys 10,119 Shares At An Average Price Of $1.59, Raising Executive Chairman Gabriele Cerrone's Total Holdings To 10,526,416 Shares

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today

Benzinga Newsdesk

OKYO Pharma Ltd

뉴스

파트너 / 기고자

벤징가 글로벌

OKYO Pharma Market Sentiment

Bulls vs Bears

Key Signals

Recent Analyst Actions

Insider & Market Activity News

PRO
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share

PRO
OKYO Pharma Announces Non-Executive Director John Brancaccio Buys 5,000 Shares At $1.48/Share, Bringing Total Holdings To 35,201 Shares

PRO
OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share

PRO
OKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per Share

PRO
OKYO Pharma Says Chairman Gabriele Cerrone, Through Panetta Partners, Increases His Holdings With Purchase Of 25,000 Ordinary Shares At $1.40 Per Share

PRO
OKYO Pharma's Panetta Partners Buys 10,119 Shares At An Average Price Of $1.59, Raising Executive Chairman Gabriele Cerrone's Total Holdings To 10,526,416 Shares

People Also Watch

Bulls vs Bears

People Also Watch

OKYO Pharma Ltd

뉴스

파트너 / 기고자

벤징가 글로벌

OKYO Pharma Market Sentiment

Bulls vs Bears

Key Signals

Recent Analyst Actions

Insider & Market Activity News

PROOKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share

PROOKYO Pharma Announces Non-Executive Director John Brancaccio Buys 5,000 Shares At $1.48/Share, Bringing Total Holdings To 35,201 Shares

PROOKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share

PROOKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per Share

PROOKYO Pharma Says Chairman Gabriele Cerrone, Through Panetta Partners, Increases His Holdings With Purchase Of 25,000 Ordinary Shares At $1.40 Per Share

PROOKYO Pharma's Panetta Partners Buys 10,119 Shares At An Average Price Of $1.59, Raising Executive Chairman Gabriele Cerrone's Total Holdings To 10,526,416 Shares

People Also Watch

Bulls vs Bears

People Also Watch

PRO
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share

PRO
OKYO Pharma Announces Non-Executive Director John Brancaccio Buys 5,000 Shares At $1.48/Share, Bringing Total Holdings To 35,201 Shares

PRO
OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share

PRO
OKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per Share

PRO
OKYO Pharma Says Chairman Gabriele Cerrone, Through Panetta Partners, Increases His Holdings With Purchase Of 25,000 Ordinary Shares At $1.40 Per Share

PRO
OKYO Pharma's Panetta Partners Buys 10,119 Shares At An Average Price Of $1.59, Raising Executive Chairman Gabriele Cerrone's Total Holdings To 10,526,416 Shares